BeyondSpring Inc(BYSI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:28 PM ET (Korea 10/31 07:28)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.16 | Insider Own | 22.31% | Shs Outstand | 41.1M | Perf Week | 49.34% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 31.9M | Perf Month | -20.88% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 5.53% | Short Float | 7.37% | Perf Quarter | -44.97% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 0.57% | Short Ratio | 2.78 | Perf Half Y | -56.79% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -31.92% | Short Interest | 2.35M | Perf YTD | -60.5% |
| Book/sh | -0.86 | P/C | 4.05 | EPS past 3/5Y | 38.52% 37.25% | ROE | - | 52W High | -73.61% ($2.44) | Perf Year | -66.29% |
| Cash/sh | 0.16 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 52.74% ($0.42) | Perf 3Y | -38.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 58.89% | Gross Margin | - | Volatility(W/M) | 18.92% 14.36% | Perf 5Y | -95.34% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.7 | EPS Q/Q | 54.02% | Profit Margin | - | RSI (14) | 54.3 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.7 | Sales Q/Q | - | SMA20 | 13.92% ($0.56) | Beta | -0.15 | Target Price | $1.25 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -2.32% ($0.66) | Rel Volume | 0.26 | Prev Close | $0.52 |
| Employees | 44 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -49.42% ($1.27) | Avg Volume(3M) | 0.85M | Price | $0.64 |
| IPO | 2017/3/9 | Option/Short | Yes/Yes | Trades | 475 | Volume | 219,060 | Change | 24.6% |
🧬 A global clinical-stage biotech company challenging the new standard of care in lung cancer treatment through 'Plinabulin,' which simultaneously induces immunotherapy and cancer cell death.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded less than usual. That is 26% of its average volume.
BYSI has weak earning power
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #455 of 597 in the industry
Based on market cap of $26M.
ABVC#454 ABVC BioPharma Inc $27M PER - BYSI#455 BeyondSpring Inc $26M PER - 
BCTX#456 BriaCell Therapeutics Corp $26M PER - 
CELU#457 Celularity Inc $26M PER - 
PLRZ#458 Polyrizon Ltd $26M PER - 
FAQ
What kind of company is BYSI?
BYSI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BYSI?
The market cap of BYSI is approximately $26M, ranking 5,118 within its sector.
What is the 52-week high and low for BYSI?
BYSI has recorded a 52-week high of $2.44 and a low of $0.42.
